• BIVDA members area

Members' Press Releases

From the monthly archives: March, 2015

We are pleased to present below all posts archived in 'March, 2015'. If you still can't find what you are looking for, try using the search box.


Proteome Sciences

Cobham, UK, March 18th 2015: Proteome Sciences plc, a global leader in proteomics, is pleased to announce that it will present four posters at the 12th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders which opens today in Nice, France. The posters highlight recent developments in Proteome Sciences’ proprietary biomarker discovery technologies for enhanced biomarker discovery, mapping of cell signaling pathways and targeted mass spectrometry methods for a blood biomarker of Alzheimer’s disease.

Read the rest of entry »

Trading Update

Proteome Sciences

9 March 2015: The Board is pleased to announce that its biomarker services division has got off to a good start in 2015 with five biomarker contracts signed. Encouragingly, there has been a strong increase in demand for SysQuant™, TMT® calibrator and TMT® MS3 services from major pharmaceutical customers and this is reflected by a growing pipeline of firm orders and quotations that should close in Q1/Q2.

Read the rest of entry »

New Philisa® ampC ID Kit Identifies Antibiotic Resistant Gram Negative Bacteria

Alpha Laboratories

The new Streck Philisa® ampC ID Kit enables rapid identification of six plasmid-mediated ampC resistance genes for pathogen surveillance in hospitals and research. When used along with standard culture, this conventional PCR kit will help to provide up-to-date information for infection control by identifying which gram-negative ampC resistant bacterial strains are present in the hospital.

Read the rest of entry »

GSK-Novartis deal close - Vaccines communication


GlaxoSmithKline plc (GSK) is pleased to announce a three-part inter-conditional transaction with Novartis AG involving its Consumer Healthcare, Vaccines & Oncology Businesses:

  • GSK and novartis will create a new world-leading Consumer Healthcare business in which GSK will have a majority control.
  • GSK will acquire Novartis' global Vaccines business (excluding influenza vaccines).
  • GSK will divest its marketed Oncology portfolio, related R&D activities and rights to its AKT inhibitor and also grant of commercialisation partner rights for future oncology products to Novartis.

Read the rest of entry »

Siemens combats increasing point-of-care workload with ecosystem approach


Siemens Healthcare Diagnostics is tackling challenges faced by point-of-care (POC) coordinators in the laboratory with an innovative ecosystem approach. The Ecosystem solution was recently launched as an integrated component of the RAPIDComm® Data Management System, an informatics solution which centrally manages Siemens in vitro diagnostics analysers and operators.

Read the rest of entry »